Baicalein reduces disuse-driven skeletal senescence and alters gut microbes in rats
Oral treatment restored bone density and mechanical strength while suppressing inflammatory markers and rebalancing intestinal bacteria in a disuse model.
Molecules (Basel, Switzerland) · Zhao X et al. · Paper published 20 Sep 2026
In a hind limb unloading rat model simulating disuse, researchers administered baicalein by gavage at 30 mg per kilogram daily for four weeks. The treatment mitigated skeletal aging, increasing bone mineral density by 1.20-fold, trabecular number by 38.04 percent, bone mineral apposition rate by 42.76 percent, and biomechanical ultimate load by 31.64 percent. Baicalein also lowered tibial senescence markers p16, p21, and p53, while attenuating high bone turnover markers in serum. In addition, the flavonoid decreased pro-inflammatory cytokines, raised anti-inflammatory factors, and shifted the gut microbiota by reducing Proteobacteria and increasing Actinobacteria and Firmicutes.
Why it matters
Mechanical disuse accelerates skeletal senescence and bone deterioration, presenting challenges in long-term immobility and spaceflight. Linking microbiome remodeling to lower bone senescence and inflammation supports the gut-bone axis as a target for protecting skeletal homeostasis.
Caveats
The findings are limited to a rodent model of mechanical unloading, meaning efficacy and safety cannot yet be assumed in humans. Additionally, the data do not establish whether gut microbiota alterations directly caused the observed improvements in bone tissue.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Baicalein Attenuates Disuse-Driven Skeletal Senescence in Association with Gut Microbiota Modulation
Zhao X, Ren T, Bai W et al.
Molecules (Basel, Switzerland) · 20 Sep 2026 · Peer-reviewed
- Relevance
- Core geroscience
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.